Namida Lab, founded in 2019 and headquartered in Fayetteville, Arkansas, is a biotechnology company dedicated to developing rapid healthcare solutions. The company's core mission is to bridge innovative scientific advancements with improved health outcomes. Namida Lab specializes in cancer screening technologies, notably offering the first at-home tear-based breast cancer screening test, Auria, which empowers women to monitor their breast health. Additionally, they provide Melody, a clinical tear-based screening test designed for use in diagnostic clinics without the need for specialized equipment.
Notable figures associated with Namida Lab include its team of experienced scientists and healthcare professionals who drive the company's research and development efforts. The company has garnered attention from investors interested in pioneering healthcare innovations. Key achievements include the successful launch of their tear-based cancer screening products, which have the potential to revolutionize early cancer detection and significantly impact public health by making screenings more accessible and less invasive.
Namida Lab's most recent funding round was for $5M (USD) in August 2021.
As of Aug 13, 2021, Namida Lab has disclosed funding of $5M (USD).

AEENA Dx
aeenadx.com

Nirmidas Biotech

Malcova
malcova.com

Hawkeye Bio
hawkeyebio.com

Signatur Biosciences
signatur.bio

The Blue Box Biomedical Solutions
thebluebox.ai

Harae Dx
haraedx.com

DotLab
dotlab.com

Early Detection
cancer.us

FYR Diagnostics
fyrdiagnostics.com

Micronoma
micronoma.com

Pharus Diagnostics
pharusdx.com

Alamar Biosciences
alamarbio.com
Airilabs

Summit Biolabs
summitbiolabs.com

Oncodea

Nanopath
nanopathdx.com

AOA Dx
aoadx.com

Mercy BioAnalytics
mercybio.com

Cellens
cellensinc.com